Loading cancer entity…
Loading cancer entity…
Variants & evidence
51 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PCNA K164R LOSS-OF-MODIFICATION1 | ||||||||
| (predisposing) | Neuroblastoma | Predisposing | D | N/A N/A | 4 | submitted | EID8032The paper showed that PCNA (p.K164R) inhibits the ubiquitination of PCNA and the variant can render cells sensitive to DNA-damaging agents and reduce activation-induced single-nucleotide substitutions… (full text at CIViC) PMID 17105346 · Arakawa et al., 2006 · Open in CIViC | civic |
Data updated 9 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.